Introduction
Prostate cancer is the most common malignancy and the second leading cause of death in males. Despite intensive study, no single therapeutic modality, short of prostatectomy, has proven universally successful in eliminating the local tumor or preventing recurrence and metastasis Greenlee et al., 2001) . Among the solid tumors, prostate cancer is distinctively amenable to gene therapy because this organ is not necessary for survival, the primary tumor can be readily treated and circulating prostate-specific antigen (PSA) can be used to monitor the efficacy of therapy ). In addition, based on the slow growth of the primary tumor, gene therapy options can provide a basis for long-term control even if the cancer is not completely destroyed. Micrometastases may also be treated using gene therapy approaches that employ strategies to augment the immunogenicity of tumor cells, thereby promoting systemic antitumor immunity . In addition, by employing improved vectors for targeting prostate cancer cells for cytolysis, apoptosis and/or tumor suppressor gene expression and by using cancer-specific apoptosis-inducing genes, such as mda-7/IL-24 (Jiang et al., 1995 (Jiang et al., , 1996 Sarkar et al., 2002a; Sauane et al., 2003) , further improvements in gene-based therapies of prostate cancer may be achievable.
Genetic therapies for prostate cancer have been examined in preclinical animal models and in patients with both localized and metastatic disease (Herman et al., 1999; Nasu et al., 1999; Rots and Curiel, 2000; Shalev et al., 2000) . These approaches have used a number of strategies, including administering suicide genes (Hall et al., 1999; Herman et al., 1999) , tumor suppressor genes (Ko et al., 1996; Sweeney and Pisters, 2000) , antiangiogenesis genes (Jin et al., 2000) , immune modulatory genes Hull et al., 2000) and various gene targeting and viral replication strategies, including promoters (such as PSA enhancer, Rodriguez et al., 1997; Gotoh et al., 1998 ; prostatespecific probasin (ARR 2 PB), Lowe et al., 2001; Xie et al., 2001 ; calveolin-1, Pramudji et al., 2001 and osteocalcin, Matsubara et al., 2001) or genetically altered viruses (Biederer et al., 2002) , permitting prostate-specific gene targeting of toxic genes and/or replication in prostate tumor cells. A key factor often limiting the success of viral therapy approaches involves low efficiency of virus transduction into tumor cells, diminishing both primary antitumor effects and an ability to localize in and effectively eliminate metastatic cancer cells . In this context, gene therapy employing a gene such as mda-7/IL-24 that selectively and efficiently kills cancer cells and can induce a profound 'bystander effect', decreasing survival in adjacent and distant tumor cells, represents an appealing molecule for cancer gene therapy (Madireddi et al., 2000; Chada et al., 2001; Gazdar and Minna, 2001; Su et al., 2001; Sarkar et al., 2002a; Lebedeva et al., 2003; Sauane et al., 2003) .
Plasticity in the tumor phenotype is observed in multiple cancers (Fisher and Grant, 1985; Leon et al., 1994; Leszczyniecka et al., 2001) . By appropriate pharmacological treatment, cancer cells can be induced to lose tumorigenic potential, irreversibly growth arrest and terminally differentiate (Fisher and Grant, 1985; Leon et al., 1994; Leszczyniecka et al., 2001) . Human melanoma cells treated with a combination of recombinant fibroblast interferon (IFN-b) and the protein kinase C activator mezerein (MEZ) display this reversion potential Jiang et al., 1993) . Using this model and subtraction hybridization, mda-7/ IL-24 was identified as a gene associated with these alterations in melanoma physiology (Jiang et al., 1995; Huang et al., 1999) . Ectopic expression of mda-7/IL-24 using a replication-defective adenovirus vector results in growth suppression and apoptosis in a wide variety of different cancers, including melanoma, glioblastoma multiforme, mesotheliomas, osteosarcoma and carcinomas of the breast, cervix, colon, lung, nasopharynx, pancreas and prostate (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Mhashilkar et al., 2001; Cao et al., 2002; Ellerhorst et al., 2002; Lebedeva et al., 2002) . The antitumor effects were independent of the genomic status of p53, RB, p16, bax and caspase-3 (Jiang et al., 1996; Su et al., 1998; Mhashilkar et al., 2001) . Although recent studies are beginning to shed light on the signaling cascades involved in mda-7/IL-24 induction of apoptosis (Pataer et al., 2002; Sarkar et al., 2002a, b; Sauane et al., 2003) , the precise mechanisms by which mda-7/IL-24 selectively induces growth inhibition and cell death in cancer cells remain to be defined. Previous studies, including those conducted in breast and pancreatic carcinoma and in malignant gliomas point toward changes in the expression of specific members of the Bcl-2-family of proteins as being important mediators of the apoptosisinducing properties of mda-7/IL-24 (Su et al., 1998 Lebedeva et al., 2002) .
In the present study, we investigated the impact of Ad.mda-7 on growth, cell cycle and survival of normal human prostate epithelial cells (HuPEC) and prostate carcinomas. Experiments also evaluated the effect of forced expression of bcl-2 and bcl-x L , two antiapoptotic Bcl-2-family proteins (Reed, 1996; Reed et al., 1996) , on Ad.mda-7-induced apoptosis of prostate tumor cells. These studies document that stable high-level expression of Bcl-2 and Bcl-x L proteins differentially protects specific prostate carcinomas from Ad.mda-7-induced apoptosis. In these contexts, the present study provides additional support for the use of Ad.mda-7 for selective cancer gene therapy, in this case for the treatment of prostate cancer.
Results

Ectopic mda-7 expression in HuPEC and prostate cancer cells by adenoviral infection
To determine the optimum multiplicity of Ad.mda-7 infection, cells were infected with a recombinant replication-incompetent adenovirus expressing green fluorescence protein (Ad.GFP) at various multiplicities of infection (m.o.i.; 10 to 150 PFU/cell) and 24 h later were analysed for GFP expression using flow cytometry. Transduction efficiency was determined by calculating the percentage of cells expressing GFP. This experimental protocol demonstrated that the optimum m.o.i., corresponding to B80-100% transduction efficiency was 30 PFU/cell for LNCaP and 100 PFU/cell for DU-145, PC-3, and HuPEC (data not shown).
To determine the efficiency of transgene expression HuPEC, DU-145, LNCaP, and PC-3 cells were infected with Ad.mda-7 or Ad.vec, total RNA was extracted and mda-7 expression was analysed by Northern blot analysis. As shown in Figure 1a , Ad.mda-7 infection resulted in both a time-and dose-dependent increase in mda-7 mRNA. The infection of HuPEC and the three prostate cancer cell lines with Ad.mda-7 gave rise to mda-7 mRNA expression B6-12 h.p.i. Infection with as little as 1 PFU/cell of Ad.mda-7 resulted in mda-7 mRNA in all the cell types within 24 h.
Although 100% of HuPEC, DU-145 and PC-3 cells were transduced with an m.o.i. of 100 PFU/cell, the expression of mda-7 mRNA could not be detected until 12 h postinfection in HuPEC and PC-3 cells, while it was present as early as 6 h.p.i. in DU-145 cells. These results suggest that additional factors contribute to transgene expression in these cells. One such factor could be the level of Coxsackie-Adenovirus (CAR) surface receptors, which mediate adenovirus attachment and uptake in cells (Bergelson et al., 1997; Tomko et al., 1997) . To determine CAR levels on the surface of the various cell types, cells were stained with a CAR-specific monoclonal antibody and receptor numbers were quantified by FACS analysis (Table 1) . CAR receptor number was lowest in PC-3 cells, which may explain the delayed kinetics of mda-7 mRNA expression in these cells (Table 1) .
The quantitation of intracellular MDA-7 protein by Western blotting indicated MDA-7 protein as early as 6 h.p.i. in LNCaP cells and 12 and 24 h.p.i. in DU-145 and PC-3 cells, respectively, with subsequent temporal increases in all cell lines (Figure 1b) . It is worth noting that in HuPEC, the expression of both mda-7 mRNA and protein was detected with similar kinetics as observed in the prostate carcinoma cells (Figure 1a, b) . Secreted MDA-7 protein was found in the supernatants from all infected cell lines, including HuPEC (unpublished data).
Ad.mda-7 expression reduces viability and induces apoptosis in prostate cancer cell lines but not in normal HuPEC
Prostate cancer cells and HuPEC were infected with Ad.mda-7 and cell viability was determined by MTT assays, trypan blue staining and clonogenic survival assays (cancer cells). Ad.mda-7 caused growth inhibition and subsequent cell death in all three prostate carcinoma cell lines, but not in normal HuPEC (Figure 2 ). Only minimal growth suppression (less than 10% growth inhibition over a 2-week period) was apparent in HuPEC following infection with 100 PFU/cell of Ad.mda-7 (Figure 2a ). In contrast, the antiproliferative effect of Ad.mda-7 was readily apparent in all three prostate cancer cell lines by day 5 (Figure 2, panels a, b) . The magnitude of growth inhibition for the three prostate carcinomas was different. LNCaP cells were most sensitive to Ad.mda-7 infection, while PC-3 cells were the most resistant to growth suppression by Ad.mda-7. Infection with Ad.vec did not significantly affect cell growth in normal prostate epithelial or Logarithmically growing prostate cells were collected, washed 2 Â with PBS and stained as described in Materials and methods with anti-CAR monoclonal antibody and FITC-labeled secondary anti-mouse goat IgG antibody. After staining, the cells were analysed by flow cytometry. CAR levels were accessed by defining ratios from the FACS histogram and the Kolmogorov-Smirnov (K-S) test as described in Young (1977) . The peak shift was calculated as a ratio (P CAR ÀP control )/P control , where P is the median of the fluorescent peak on FACS histograms. The D value represents the differences between the two curves (K-S test); higher numbers reflect enhanced binding and increased CAR receptor number The total RNA was extracted and analysed by Northern blotting as described in Materials and methods. After the blots were probed with a random-primed 32 P-labeled mda-7/IL-24 cDNA probe, they were stripped and reprobed with a random-primed 32 P-labeled gapdh cDNA probe. (b) Cells were infected with 100 PFU/cell of Ad.mda-7 (30 PFU/ cell for LNCaP cells), and protein samples were collected as described in Materials and methods. Samples (25 mg of total protein) were run on 12.5% SDS-PAGE, transferred onto nitrocellulose membranes and stained with rabbit anti-MDA-7 antibody Bcl-2 and Bcl-x L protect human prostate cancer cells IV Lebedeva et al carcinoma cells (Figure 2 ). Qualitatively similar results were obtained using MTT assays to monitor cell viability (Figure 2b ). Long-term clonogenic assays also confirmed growth-inhibitory and cell-killing effects of Ad.mda-7 in prostate cancer cells (Figure 2c ). Additionally, infection with Ad.mda-7 inhibited anchorage-independent growth of prostate carcinoma cells (data not shown). Previous studies demonstrate that Ad.mda-7 induces apoptosis in a wide range of human cancers, but not in normal cells (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Mhashilkar et al., 2001; Lebedeva et al., 2002; Pataer et al., 2002; Sarkar et al., 2002b) . DAPI staining of Ad.mda-7-infected prostate cancer cells demonstrated characteristic apoptotic morphological changes, including nuclear fragmentation, in the prostate cancer cells by 24 h.p.i. (Figure 3a) . In contrast, infection with control Ad.vec did not cause similar changes in cellular morphology. Annexin-Vbinding assays and hypodiploidy assays quantified the effect of Ad.mda-7 on apoptosis induction in prostate carcinomas and HuPEC. Annexin-V-positive apoptotic cells were detected earliest in Ad.mda-7-infected LNCaP cells (16-18 h.p.i.) and at later time points in DU-145 and PC-3 cells, at 24 and 30 h.p.i., respectively (Figure 3b ). The percentage of apoptotic prostate carcinoma cells increased significantly (about twofold) in Ad.mda-7-infected as compared to control-uninfected and Ad.vec-infected cells.
The TUNEL method employs fluorescent labeling of DNA strand brakes generated during apoptosis in fixed cells by terminal deoxynucleotidyl transferase. Subsequent flow cytometry analysis documented a high level of DNA fragmentation after Ad.mda-7 infection in prostate cancer cells that was comparable to DNase treated controls (Figure 3c ). Ad.vec infection did not induce DNA fragmentation. PI does not intercalate into highly fragmented apoptotic DNA, permitting determination of the percentage of cells in the apoptotic A 0 population following Ad.mda-7 or Ad.vec infection. This assay confirmed that LNCaP cells were the most sensitive prostate cancer cells, dying within B3 days after Ad.mda-7 infection (Figure 3d ). By 3 days postinfection with Ad.mda-7, B40% of DU-145 and B30% of PC-3 cells demonstrated apoptotic DNA fragmentation. In contrast, except for a small increase in A 0 DNA content 24 h after Ad.mda-7 or Ad.vec infection, only control baseline A 0 DNA content was evident in HuPEC 48 or 72 h.p.i. with the different viruses. Ad.vec infection did not elevate apoptotic A 0 populations in any of the prostate cell lines. The results of both assays correspond with viability assays indicating that LNCaP cells are more sensitive than DU-145 and PC-3 cells to Ad.mda-7.
Adenovirus-transduced mda-7 induces G 2 M arrest in prostate cancer cells but not in HuPEC PI staining of fixed cells and subsequent flow cytometry assays evaluated the effect of Ad.mda-7 on cell-cycle progression (Figure 4) . According to previous studies, Figure 2 Adenovirus-mediated mda-7 expression inhibits the in vitro growth of prostate carcinoma cells, but not normal early passage prostate epithelial cells. The various cell types were uninfected (control) or infected with 100 PFU/cell of Ad.vec or Ad.mda-7 (30 PFU/cell for LNCaP cells). (a) Cell numbers were determined over a 14-day period (panel a), with a medium change at days 4, 7 and 10. Triplicate samples varied by o 10%. (b) Cells were seeded in 96-well plates and treated the next day as described in 'Results'. After 5 days, the medium was removed, and cells were stained with MTT as described in Materials and methods. Experiments were repeated three times in quadruplicates, and the results are presented as mean7s.e. Statistical analysis of the results was performed using the Analysis ToolPack provided by Microsoft Excel. A Student's two-sample t-test, assuming unequal variances, was used to determine the equality of the means of two samples. The confidence level (a) was 0.05. (c) The next day after infection, cells were replated at low density as described in Materials and methods. After 3 weeks, the cells were fixed with 4% formaldehyde and stained with a 5% (w/w) solution of Giemsa stain in water. Colonies 450 cells were enumerated. The results are expressed as the average of triplicate samples7s.e.
Ad.mda-7 infection induces an increase in the percentage of specific cancer cell types in the G 2 /M phase of the cell cycle (Saeki et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002; Su et al., 2003) . Similarly, Ad.mda-7 induced a G 2 /M accumulation in all three prostate carcinoma cell lines, but not in HuPEC (Figure 4 ). This effect was first noted at 48 h.p.i. and became most pronounced 72 h.p.i. The magnitude of this cell-cycle effect was greatest in LNCaP cells. In contrast, only a marginal increase (o2%) in cells in the G 2 /M phase of the cell cycle was apparent after Ad.mda-7 infection of HuPEC (Figure 4 ). On the contrary, Ad.vec infection did not affect cell cycle in any of the cell types.
Modulation of Bcl-2 family proteins in prostate carcinoma cells following Ad.mda-7 infection
Previous studies in multiple tumor models, including breast and pancreatic carcinomas, melanomas and malignant gliomas, indicate that Ad.mda-7 induces changes in the levels and ratio of pro-(Bax and/or Figure 3 Overexpression of mda-7 causes apoptosis selectively in prostate cancer cells. Cells were infected with 100 PFU/cell of Ad.mda-7 (30 PFU/cell for LNCaP cells) and all assays were performed 24 h after infection as described in Materials and methods. (a) To evaluate characteristic apoptotic morphology with fluorescence microscopy, cells were seeded on glass slides and fixed with 90% ethanol containing 5% (w/w) acetic acid for 1 h at room temperature. After two washes with PBS, cells were stained for 30 min in the dark at room temperature with 0.5 mg/ml DAPI in PBS. The nuclear fragmentations were visualized by using a fluorescence microscope equipped with a UV-2A filter and Nikon 6006 photographic camera. Apoptotic cells were recognized by condensation of nuclear chromatin and its fragmentation. Typical fields are presented for each treatment. (b) For Annexin-V-binding assay of apoptosis, cells were stained with FITC-labeled Annexin-V and PI and immediately analysed by flow cytometry. The percentage of early apoptotic cells (only Annexin-V stained) and late apoptotic and necrotic cells (stained with both Annexin-V and PI) was calculated using the CellQuest software (Becton Dickinson, San Jose, CA, USA). (c) Induction of apoptosis by Ad.mda-7 was assessed by TUNEL assay. After treatment with Ad.vec or Ad.mda-7, cells (1 Â 10 6 aliquots) were trypsinized, washed and fixed with an equal amount of a freshly prepared paraformaldehyde solution (4% in PBS, pH 7.4) as described in Materials and methods. Following fixation, cells were permeabilized with 0.1% Triton s X-100 in 0.1% sodium citrate on ice and labeled using the fluorescein cell death detection kit (Boehringer Mannheim, Germany) according to the manufacturer's instructions. After labeling, cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Control cells were treated with DNase to introduce DNA breaks. (d) Induction of apoptosis as monitored by A 0 DNA content by Ad.mda-7 in prostate carcinomas. The indicated cells were untreated (control) or infected with Ad.vec or Ad.mda-7 and harvested at 24, 48 and 72 h.p.i., fixed and stained with PI as described in Materials and methods. The percentage of the cells in the A 0 fraction was calculated using the CellQuest software (Becton Dickinson). All experiments were performed a minimum of 3 times with s.d.o5%
Bcl-2 and Bcl-x L protect human prostate cancer cells IV Lebedeva et al Bak) to antiapoptotic (Bcl-2 and/or Bcl-x L ) proteins (Su et al., 1998 Lebedeva et al., 2002) . Moreover, this change, which occurs in cancer but not in normal cells, may be a defining element in mda-7/IL-24 induction of apoptosis. Analysis of the expression of Bcl-2 family proteins by Western blotting following Ad.mda7 and Ad.vec infection confirmed a differential effect on the levels of Bcl-x L , Bcl-2, Bax and Bak in the three prostate carcinoma cells following Ad.mda-7 infection ( Figure 5 ). The relative change in expression of the different proteins relative to EF-1a protein was quantified by laser-scanning densitometry and the ratio of Ad.vec to Ad.mda-7-infected samples was determined. An example of this analysis in PC-3, DU-145 and LNCaP cells 72 h.p.i. with Ad.mda-7 and Ad.vec is shown in Table 2 . In PC-3 cells, Bcl-2 protein remained unchanged following Ad.mda-7 infection, whereas Bclx L proteins were decreased more than twofold, and the levels of Bak and, to a lesser extent, Bax proteins were elevated (2.9-and 1.4-fold, respectively). In DU-145 cells, Ad.mda-7 decreased Bcl-x L and Bcl-2 protein levels (2.3-and 1.5-fold, respectively), whereas Bak protein expression was increased 1.8-fold. As anticipated, no Bax protein was expressed in DU-145 cells, because of mutations in both alleles of this gene . In LNCaP cells, Bcl-2 (2.6-fold) and Bcl-x L protein levels (2.3-fold) were decreased by Ad.mda-7, whereas Bax and, to a marginal extent, Bak proteins were elevated (2.2-and 1.3-fold, respectively). In contrast, the levels of the various pro-and antiapoptotic proteins did not change significantly in HuPEC following infection with Ad.mda-7 ( Figure 5 , Table 2 ). These studies provide further support for the hypothesis that Ad.mda-7 increases the ratio of pro-to antiapoptotic proteins, thereby tipping the balance of cancer cells from survival to programmed cell death (Su et al., 1998 Lebedeva et al., 2002) .
Generation and characterization of Bcl-2 and Bcl-x L overexpressing prostate cancer cell lines
Bcl-2 and Bcl-x L play critical roles in inhibiting the apoptotic pathway (Reed, 1995 (Reed, , 1997 . Based on previous studies (Su et al., 1998 Lebedeva et al., 2002) 
Bcl-2 family protein expression levels were determined by Western blot analysis as described in Materials and methods and quantitatively analysed using laser-scanning densitometry and the NIH Image Version 1.61 software. All results were calculated as a percentage of protein expression in Ad.mda-7-versus Ad.vec-infected cells 72 h.p.i. (Figure 8 , panel c) and an increase in the size of colonies following Ad.mda-7 infection (data not shown). Although protection was significantly less than with Bcl-2 overexpres- Figure 6 Bcl-x L overexpression protects DU-145 prostate carcinoma cells from Ad.mda-7-induced growth inhibition. (a) Protein lysates were collected from G418-resistant stable clones of DU-145 cells overexpressing Bcl-2, Bcl-x L or containing an empty vector (neo). Samples (20 mg) were run on 12% SDS-PAGE, transferred onto a nitrocellulose membrane and stained with rabbit anti-Bcl-2 and antiBcl-x L antibodies as described in Materials and methods. Equal loading of protein was confirmed by EF-1a staining (data not shown).
(b) Neo-resistant (mock transfected), Bcl-2 and Bcl-x L overexpressing DU-145 clones were seeded in 96-well plates and infected with 100 PFU/cell of Ad.vec or Ad.mda-7. MTT assays were performed on day 5 after infection as described in Materials and methods, and cell viability was determined as the ratio of optical density of Ad.mda-7-to Ad.vec-infected cells. All experiments were performed at least three times using quadruplicate samples. The results are presented as mean7s.e. (c) Neo-resistant (mock transfected), Bcl-2 and Bcl-x L overexpressing individual and pooled clones and transiently transfected DU-145 cells were infected with 100 PFU/cell of Ad.vec or Ad.mda-7 and replated the next day at low density as described in Materials and methods. After 3 weeks, the cells were fixed with 4% formaldehyde and stained with a 5% (w/w) solution of Giemsa stain in water. Colonies 450 cells were enumerated. The results are expressed as the average of triplicate samples7s.e. Abbreviations: neo, neomycin resistant; x L -cl, Bcl-x L -overexpressing clones; B2-cl, Bcl-2-overexpressing clones; x L -pool, pooled Bcl-x L -overexpressing clones; B2-pool, Bcl-2-overexpressing pooled clones; Bcl-x L -trans, Bcl-x L -transiently transfected cells; Bcl-2-trans, Bcl-2-transiently transfected cells sion, overexpression of Bcl-x L did permit the survival of one LNCaP clone (xL-cl5, B20%) (Figure 8c ). In contrast, clonal survival in parental and the neo-resistant clones was severely compromised (0-2% of parental LNCaP and neo-resistant cells) following infection with Ad.mda-7.
Since several independent Bcl-2 and Bcl-x L overexpressing clones of each prostate cancer cell type demonstrated comparable sensitivity to Ad.mda-7-induced apoptosis, we chose one clone of each cell type (reflecting the average sensitivity profile) to perform further studies (Figure 9, panel a) . Infection of Bcl-2 and Bcl-x L overexpressing DU-145 (xL-cl53; B2-cl42), PC-3 (xL-cl72; B2-cl5) and LNCaP (xL-cl; B2-cl55) clones with Ad.mda-7 identified several different sized MDA-7 proteins by Western blotting (Figure 9, panel b) . In general, the expression of MDA-7 protein was timedependent; however, the level of expression varied among the clones. The highest relative protein expression was detected in the Bcl-2 overexpressing DU-145 and PC-3 clones and in the control neomycin-resistant PC-3 clone. In contrast, all three LNCaP clones (neomycin-resistant and Bcl-2 and Bcl-x L overexpressing) revealed similar kinetics of MDA-7 expression. The reason for the differential levels of MDA-7 protein in specific clones is not known, but could reflect clonal Bcl-2 and Bcl-x L protect human prostate cancer cells IV Lebedeva et al heterogeneity in the parental population. Confirmation of this possibility would require analysis of a large number of individual clones of each cell type. Since the levels of CAR receptors are similar between the different sets of clones analysed (data not shown), differences in transgene expression between the various DU-145 and PC-3 clones may be the primary factor mediating differential expression of MDA-7 protein following infection with Ad.mda-7.
Bcl-2 and Bcl-x L protein overexpression differentially protect prostate cancer cells from Ad.mda-7-induced apoptosis
The results of viability (MTT) and long-term survival (clonogenic) assays imply that Bcl-2 and Bcl-x L can differentially protect prostate cancer cells from apoptosis induced by mda-7/IL-24. Based on this consideration, experiments were performed to document differential protection from apoptosis by these antiapoptotic proteins. DAPI staining confirmed characteristic apoptotic laddering in parental and all the prostate cancer clones following Ad.mda-7 infection, except Bcl-x L overexpressing DU-145 and PC-3 clones and the Bcl-2 overexpressing LNCaP clones (data not shown). The extent of apoptosis was estimated by Annexin-Vbinding assays and PI staining followed by FACS assays. Bcl-x L overexpression blocked phosphatidyl serine (PS) exposure in PC-3 cells ( Figure 10 , panel a; Table 3 ). The percentage of Annexin-V-positive cells after Ad.mda-7 infection in the PC-3/Bcl-x L clone was 7.970.8% as compared to 14.170.4% in the PC-3/neo and 18.171.5% in PC-3/Bcl-2 clones. In DU-145 cells, ectopic overexpression of Bcl-2 and Bcl-x L blocked PS Cells overexpressing Bcl-2 or Bcl-x L and expressing the G418 resistance gene, were infected with 100 PFU/cell (DU-145, PC-3) or 30 PFU/cell (LNCaP), and 24 h later, Annexin-V-binding assays were performed as described in Materials and methods. Percentage of Annexin-V-positive cells was determined by FACS assay Figure 9 Adenovirus-mediated infection causes MDA-7 overexpression in prostate cancer cell clones overexpressing Bcl-2 and Bcl-x L proteins. (a) Protein lysates were collected from G418-resistant stable clones of prostate cancer cells overexpressing Bcl-2, Bcl-x L or containing an empty vector (neo). Samples (20 mg) were run on 12% SDS-PAGE, transferred onto a nitrocellulose membrane and stained with rabbit anti-Bcl-2 and anti-Bcl-x L antibodies as described in Materials and methods. Equal loading of protein was confirmed by EF-1a staining (data not shown). (b) Neomycin-resistant, and Bcl-2 and Bcl-x L overexpressing prostate cancer cell clones were infected with 100 PFU/cell of Ad.vec or Ad.mda-7 (30 PFU/cell for LNCaP transfectants) and protein lysates were collected in RIPA buffer. Samples (20 mg of total protein) were run on 12% SDS-PAGE, transferred onto a nitrocellulose membrane and stained with rabbit anti-MDA-7 antibodies Figure 10, panel b) . Flow cytometry assays of A 0 populations demonstrated full protection against apoptosis by Bcl-x L in PC-3 cells (o5% cells in the A 0 population 96 h.p.i. compared to B70% in the neoresistant and B60% in Bcl-2 overexpressing PC-3 clones). Bcl-2 overexpression provided complete protection against Ad.mda-7-induced apoptosis in LNCaP cells even 72 h.p.i., when parental cells and the other clones of LNCaP were already dead. Interestingly, at early times (24 and 48 h.p.i.), both Bcl-x L and Bcl-2 prevented A 0 population increases in DU-145 clones. However, 72 h.p.i., A 0 populations in Ad.mda-7-infected DU-145 cells overexpressing Bcl-2 (DU-145/Bcl-2) increased significantly (up to B18%), while this population remained at B5% for the Ad.mda-7-infected DU-145/Bcl-x L clone.
Discussion
It is now firmly established that mda-7/IL-24, when administered to cancer cells of diverse origins by adenovirus transduction, can induce growth suppression and cell death, whereas normal cellular counterparts are spared (Jiang et al., 1996; Su et al., 1998 Su et al., , 2001 Ad.mda-7 infection in neo-, Bcl-2 and Bcl-x L overexpressing stable transfected clones of prostate cancer cells. Cells infected with 100 PFU/cell of Ad.vec or Ad.mda-7 (or 30 PFU/cell for LNCaP cells) were harvested at 24, 48, 72 and 96 h.p.i., fixed and stained as described in Materials and methods. Viable cells were gated using the CellQuest Software, and the A 0 cell population was determined for each cell type as described in Materials and methods. The experiment was repeated at least three times, and s.d. did not exceed 5%
Bcl-2 and Bcl-x L protect human prostate cancer cells IV Lebedeva et al 2002; Mhashilkar et al., 2001; Lebedeva et al., 2002) . The present study extends these findings to normal and carcinoma cells of prostate lineage. We demonstrate that despite similar kinetics of mda-7 mRNA and protein expression and secretion in HuPEC and prostate carcinoma cell lines following Ad.mda-7 infection, growth suppression and subsequent apoptosis induced by Ad.mda-7 are evident only in prostate cancer cells and not in HuPEC. These unique properties of mda-7/IL-24 make this gene a very attractive candidate for cancer gene therapy, even though its precise mechanism of cancer selective action remains unclear (Sarkar et al., 2002a; Lebedeva et al., 2003; Sauane et al., 2003) .
In this study, we have begun to elucidate the potential role of the antiapoptotic proteins Bcl-2 and Bcl-x L , the expression of which is downregulated by Ad.mda-7 infection, in mediating Ad.mda-7-induced apoptosis. Bcl-2-family proteins are well-known regulators of cell death and can be divided into pro-(including Bax and Bak) and antiapoptotic (including Bcl-2 and Bcl-x L ) members (Reed, 1996; Reed et al., 1996) . Several different mechanisms, including heterodimerization between pro-and antiapoptotic members of the Bcl-2-family, have been proposed for apoptosis regulation by these proteins (Oltvai et al., 1993; Sedlak et al., 1995; Yin et al., 1995; Reed, 1997; Cory, 1998, 2001) . Different apoptotic stimuli might reset the ratio between the pro-and antiapoptotic proteins, thereby increasing free Bax and Bak and their homodimers, and thus promoting cell death (Selvakumaran et al., 1994; Ibrado et al., 1997) . Alterations in these ratios following Ad.mda-7 infection may determine differential sensitivities of cancer cells versus normal cells to mda-7/IL-24 (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002) . According to our data, this also appears to be the case in prostate carcinomas following infection with Ad.mda-7. Infection of HuPEC cells with Ad.mda-7 did not change the levels of expression of pro-and antiapoptotic members of the Bcl-2-family gene products ( Figure 5 , Table 2 ). In contrast, increases in the ratio of pro-to antiapoptotic proteins were evident in PC3, DU-145 and LNCaP cells infected with Ad.mda-7. By comparing the level of modulation of specific Bcl-2-family members, a role for these proteins in regulating mda-7-induced apoptosis can be envisioned. Since Bcl-2 remained unchanged in PC-3 cells after Ad.mda-7 infection, it is likely that this protein is not central for mda-7-induced apoptosis in these cells. However, these protein expression data ( Figure 5 and Table 2 ) are not sufficient to make definitive conclusions relative to the mechanism by which Ad.mda-7 induces apoptosis.
The significance of Bcl-2 and Bcl-x L downregulation in Ad.mda-7-mediated apoptosis was evaluated by stably overexpressing these molecules in prostate cancer cells. Our results demonstrate that Bcl-2 and Bcl-x L differentially block Ad.mda-7-mediated growth inhibition and subsequent death in prostate carcinomas, with Bcl-x L providing protection to PC-3 and DU-145 cells, and Bcl-2 providing protection to LNCaP cells (Figures 6, 7, 8 and 10) . The level of protection does not directly correlate with the level of mda-7/IL-24 expression in most of the stable transfectants (Figure 9, panel b) . Both Ad.mda-7-sensitive DU-145/neo and Ad.mda-7-resistant DU-145/Bcl-x L clones display comparable levels of MDA-7 protein expression. Correspondingly, in three different LNCaP clones, MDA-7 levels are similar. In contrast, in the PC-3 transfectants, a correlation between MDA-7 protein levels and sensitivity is apparent, with MDA-7 expression levels being lower in a resistant PC-3/Bcl-x L clone than in a sensitive PC-3/neo and a sensitive PC-3/Bcl-2 clone following Ad.mda-7 infection. However, since only Bcl-x L levels changed following Ad.mda-7 infection in parental PC-3 cells, it is more likely that overexpression of Bcl-x L , and not Bcl-2, would provide protection in these cells. Again, the possibility of transcriptional regulation of mda-7/IL-24 expression by Bcl-x L overexpression cannot be excluded.
Interesting insights were obtained from the studies of Bcl-2 and Bcl-x L overexpressing DU-145 clones. In the early stages of apoptosis, both Bcl-2 and Bcl-x L overexpression afforded some protection (although greater in the case of Bcl-x L overexpression) against Ad.mda-7 action based on short-term MTT viability and Annexin-V-binding assays (Figure 6 , panel b, and Figure 10 ). In the case of Annexin-V binding, the percentage of apoptotic cells did not change significantly 24 h after Ad.mda-7 treatment of Bcl-2 and Bcl-x L overexpressing clones compared with Ad.vec-infected cells (Figure 10 ). Based on DAPI staining, the percentage of cells with characteristic apoptotic morphology was also comparable in DU-145/Bcl-x L and DU-145/Bcl-2 24 h after infection with Ad.mda-7 (data not shown). Bcl-2 overexpression also blocked, up to 48 h after infection, the accumulation of cells in the A 0 population. However, 72 h.p.i., the A 0 population of DU-145/Bcl-2 cells was significantly increased and became comparable to that of sensitive DU-145/neo cells (Figure 10,  panel b) . Accordingly, long-term clonogenic assays also demonstrated that only Bcl-x L provided protection for DU-145 cells (Figure 6, panel c) . Multiple reports confirm that prevention from apoptosis by Bcl-2 following DNA damage does not guarantee enhanced long-term tumor cell survival (Sentman et al., 1991; Collins et al., 1992; Strasser et al., 1994; Gilbert et al., 1996; Lock and Stribinskiene, 1996; Kyprianou et al., 1997) .
In the case of PC-3 and DU-145 cells, the proapoptotic members of the Bcl-2-family that are bound by Bcl-x L may be more relevant or better neutralized than those that bind Bcl-2. Alternatively, the differential protection provided by Bcl-x L in PC-3 and DU-145 cells might be explained by differences in repertoires of endogenous Bcl-x L antagonist proteins expressed in these cell lines, such as Bad, Bik, Bid, Hrk, Bim, Bfm and Bcl-G s . A similar reason could account for the selective protection from apoptosis induction by Ad.mda-7 afforded by Bcl-2, and the failure of Bcl-x L to protect in LNCaP cells, since Bcl-2 and Bcl-x L vary in their binding ability for many antagonistic members of the Bcl-2 family (Cheng et al., 1996; Adachi and Imai, 2002; Shangary and Johnson, 2002) . Understanding the mechanisms underlying these differential responses in specific prostate carcinoma cells to these structurally and functionally similar Bcl-2-family member proteins will provide insights into their mode of action and will also prove informative in understanding apoptosis inducing properties of the mda-7/IL-24 in cancer cells. However, even though we compared the sensitivity of several clones to Ad.mda-7, clonal variations within prostate cancer cells could also contribute to the differential protection afforded by Bcl-2 and Bcl-x L . Thus, definitive evidence that Bcl-2 and Bcl-x L differentially protect from Ad.mda-7-induced apoptosis in prostate cancer cells would require use of conditional promoters or other methods.
Bcl-2/Bcl-x L may regulate caspase activation through sequestration of unidentified caspase adaptors/activators (Cory and Adams, 2002) . Moreover, Bcl-2 and Bcl-x L could directly interact as substrates with different subsets of caspases (Cheng et al., 1997; Clem et al., 1998; Grandgirard et al., 1998) . These factors might be important for LNCaP cells where Bcl-2, but not Bcl-x L , overexpression provided protection against Ad.mda-7-mediated apoptosis, indicating that the caspase machinery activated by mda-7/IL-24 in LNCaP cells might be preferentially inhibited only by Bcl-2.
It is also possible that additional cellular factors are responsible for the differential protection afforded by Bcl-x L or Bcl-2 in specific prostate cancer cells from Ad.mda-7-induced apoptosis. Potential cellular factors such as Stat, NF-kB, AP-1, might differentially regulate transcription of bcl-x L , bcl-2 and other Bcl-2-family members (Beg and Baltimore, 1996; Sevilla et al., 2001; Battle and Frank, 2002) . In addition, post-translational modifications, such as Bcl-2 phosphorylation or Bcl-x L deamidation, which might be triggered by Ad.mda-7 infection could contribute to the differential protection afforded by these molecules (May et al., 1994; Haldar et al., 1995 Haldar et al., , 1996 Ito et al., 1997; Ling et al., 1998; Poruchynsky et al., 1998; Scatena et al., 1998; Deverman et al., 2002) . Further experimentation is necessary to determine if these factors/processes contribute to the differential protection of prostate cancer cells from apoptosis induction by Ad.mda-7.
Of direct relevance to the use of Ad.mda-7 for the therapy of prostate cancer is the relationship between changes in expression of Bcl-x L and Bcl-2 as they occur in vivo in prostate tumors to the results observed, that is, differential protection from apoptosis, following ectopic expression of these proteins in prostate cancer cells in vitro. The expression of both Bcl-x L and Bcl-2 proteins occurs in prostate carcinomas (Colombel et al., 1993; Krajewski et al., 1994; Krajewska et al., 1996) . Bcl-2 immunostaining increases with the Gleason grade of the prostate tumor. Bcl-2 expression in tissues has been evaluated as an indicator for poor prognosis in prostate carcinoma (Bauer et al., 1996; Keshgegian et al., 1998; Sullivan et al., 1998; Baif et al., 1999) . Moreover, Bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence (McDonnell et al., 1992; McConkey et al., 1996; Beham et al., 1998; Kajiwara et al., 1999) . Bcl-x L overexpression has been found to correlate with resistance to druginduced apoptosis in prostate cancer cells (Liu and Stein, 1997; Amundson et al., 2000; Lebedeva et al., 2000; Li et al., 2001) . Forced overexpression of Bcl-2 has been shown to desensitize prostate cancer cells to apoptotic stimuli (Raffo et al., 1995; Tu et al., 1995; Kyprianou et al., 1997) . However, it is unclear whether the function of Bcl-2/Bcl-x L at supraphysiological intracellular levels, observed in our transfected clones, bears resemblance to its normal function in the context of in vivo prostate tumors. Further studies are necessary to compare the levels of expression of Bcl-2/Bcl-x L in prostate carcinoma tissues in vivo with the levels of expression of these proteins in the stable transfectants analysed in the present study. Even if the levels should be comparable, which is highly unlikely, this problem would not be insurmountable. By appropriate manipulation with cytotoxic chemotherapeutic agents (Berchem et al., 1995; Tu et al., 1995; Liu and Stein, 1997) and/ or antisense oligonucleotides (Lebedeva et al., 2000; Miyake et al., 2001; Su et al., 2001) , it may be possible to favorably alter the balance between pro-and antiapoptotic proteins in a particular tumor, making it susceptible to mda-7/IL-24-induced apoptosis.
In summary, Ad.mda-7 selectively induces apoptosis in prostate cancer cells, irrespective of their p53, Rb or bax gene status, without affecting growth or survival in normal prostate epithelial cells. A potential functional role for changes in Bcl-2 family proteins in the apoptotic process is suggested by the ability of Ad.mda-7 infection to modify the expression of these proteins selectively and by ectopic expression of either Bcl-x L or Bcl-2 prevent to apoptosis induced by Ad.mda-7 in specific prostate cancer cell lines. An important finding is that overexpression of Bcl-x L or Bcl-2 can differentially protect specific prostate cancer cells from death induced by mda-7/IL-24. Further studies are required to determine if these alterations in Bcl-2 family proteins will impact the ability of Ad.mda-7 to provide therapeutic value for this cancer. Regardless, the availability of prostate carcinoma cell clones exhibiting stable differences in their susceptibility to Ad.mda-7-induced apoptosis represents a valuable resource for defining the requisite gene expression changes mediating sensitivity or resistance to apoptosis induced by mda-7/ IL-24.
Materials and methods
Cell lines, transfections and culture conditions
Human DU-145, PC-3 and LNCaP prostate carcinoma cell lines were obtained from the ATCC and cultured in RPMI 1640 supplemented with 10% FBS, sodium pyruvate and nonessential amino acids at 371C in a 5% CO 2 95% air humidified incubator. Normal human prostate epithelial cells (HuPEC) were purchased from BioWhittaker and cultured in PrEGMt Prostate Epithelial Cell Growth Medium containing all the supplements recommended by the manufacturer. To obtain Bcl-2 and Bcl-x L overexpressing clones, prostate carcinoma cells were transfected with Lipofectin s reagent and a neomycin-selectable pSFFV/bcl-x L or pSFFV/bcl-2 plasmid (provided by Dr S Korsmeyer, Washington University School of Medicine, St Louis, MO, USA) or with a control, neomycinresistant expression vector pSFFV. Individual clones were selected after approximately 3-4 weeks maintenance in culture medium containing 1 mg/ml G418 sulfate. Cells were infected with 100 PFU/cell of Ad.mda-7 or Ad.vec (30 PFU/cell for LNCaP cells) and analysed as described. For transient transfection assays, 2 Â 10 5 cells were transfected with 2 mg of pSFFV/bcl-x L or pSFFV/bcl-2 plasmids and SuperFect Transfection Reagent (QIAGEN Inc., Valencia, CA, USA) 24 h prior to infection with Ad.mda-7 or Ad.vec as described (Jiang et al., 1996; Su et al., 1998) .
Virus construction, plaque assays and virus infection protocol
The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (Su et al., 1998) . Briefly, the coding region of the mda-7/IL-24 gene was cloned into a modified Ad expression vector pAd.CMV under control of the cytomegalovirus immediate early promoter (FalckPedersen et al., 1994), thus allowing high-level expression of the cloned sequence and appropriate RNA processing (FalckPedersen et al., 1994) . The recombinant virus was created in vivo in 293 cells (Graham et al., 1977) by homologous recombination between mda-7-containing vector and plasmid JM17, which contains the whole of the Ad genome cloned into a modified version of pBR322 (McGrory et al., 1988) . The recombinant virus is replication defective in human cells except 293 cells, which express adenovirus E1A and E1B. Following transfection of the two plasmids, infectious virus was recovered, the genomes were analysed to confirm the recombinant structure and then the virus was plaque purified, all by standard procedures (Volkert and Young, 1983) . Stock virus preparations were diluted in serum-free RPMI 1640 medium and inoculated onto cell monolayers at the indicated m.o.i. After 2 h virus adsorption at 371C with rotation every 15 min, the virus inoculum was removed, fresh complete RPMI 1640 medium was added to the infected monolayer cultures and cells were incubated at 371C for the indicated times. The optimal m.o.i. was determined by infection with dilutions of a replication-incompetent adenovirus expressing green fluorescence protein (GFP; Ad.GFP) in a range 5-100 PFU/cell. After 24 h, cells were collected, washed twice with PBS and analysed by flow cytometry for the expression of GFP.
Detection of CAR receptors on the cell surface CAR receptors were determined as previously described (Lebedeva et al., 2002; Su et al., 2003) . Briefly, cells were harvested by trypsinization, washed two times with PBS and stained with 1 : 1000 dilution of monoclonal anti-CAR antibody, for 1 h at 371C. After additional washings with PBS (2 Â 5 min), cells were stained in the dark for 1 h at 371C with a 1 : 500 dilution of fluorescein-labeled goat anti-mouse immunoglobulins (BioSource International, Camarillo, CA, USA). After washings with PBS, cells were analysed by flow cytometry (5 Â 10 5 cells per sample). Unstained cells and cells stained with monoclonal anti-SV40 antibody (Santa Cruz, CA, USA) and with secondary antibody only were used as controls. Two methods were used for semiquantitation of the results. The shift of FL1 peak was calculated as the difference in peak channels between the control (cells unstained or stained with nonspecific antibody) and the experimental cells stained with anti-CAR antibody relative to the position of the control cell peak channel. The second method used the Kolmogorov-Smirnov (K-S) test for overlaid histograms (Young, 1977) . The calculation computes the summation of the overlaid curves and determines the greatest difference between the summation curves (K-S statistics). The D value indicates the greatest difference between the two curves.
Cell death assays
Viability assay Cells were seeded in 24-well tissue culture plates at a density of 1 Â 10 4 cells per well. The next day, cells were infected as described. At the indicated times after infection, cells were trypsinized, stained with trypan blue and viable cells were counted using a hemocytometer.
MTT assay Cells were seeded in 96-well tissue culture plates (1.5 Â 10 3 cells per well) and treated the next day as described in 'Results'. At the indicated time points, the medium was removed, and fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 371C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. The optical density from the plates was read on a Dynatech Laboratories MRX microplate reader at 540 nm. A statistical analysis of the results was performed using the Analysis ToolPack provided by Microsoft Excel. A Student two-sample t-test, assuming unequal variances, was used to determine the equality of the means of two samples. The confidence level (a) was 0.05.
Clonogenic survival assay Cells were treated as described in the text. The next day, after trypsinization and counting, cells were replated in 60 mm dishes (100 cells per dish) in triplicate. After 2-3 weeks, cells were fixed with 4% formaldehyde and stained with a 5% (w/w) solution of Giemsa stain in water. Colonies 450 cells were enumerated.
Apoptosis and necrosis assay (Annexin-V-binding assay) Cells were trypsinized and washed once with complete media. Aliquots of cells (5 Â 10 5 ) were resuspended in complete media (0.5 ml) and stained with FITC-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA, USA) according to the manufacturer's instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. Flow cytometry was performed immediately after staining.
Fluorescent microscopy evaluation of cell death After transfection, cells were washed once with PBS and fixed in 90% ethanol, containing 5% (w/w) acetic acid for 1 h at room temperature. After two washes with PBS, cells were stained for 30 min in the dark at room temperature with 0.5 mg/ml DAPI in PBS. Nuclear fragmentation was visualized using a fluorescence microscope equipped with a UV-2A filter and Nikon 6006 photographic camera. Apoptotic cells were identified by condensation of nuclear chromatin and its fragmentation.
TUNEL assay After treatment, cells were trypsinized, washed twice with PBS/1%BSA and resuspended in PBS/ 1%BSA. Cells (1 Â 10 6 ) were fixed with an equal amount of a freshly prepared paraformaldehyde solution (4% in PBS, pH 7.4). After 30 min incubation at room temperature, cells were washed with PBS and resuspended in a permeabilization solution (0.1% Triton s X-100 in 0.1% sodium citrate) for 2 min on ice. After an additional wash with PBS, cells were labeled using fluorescein cell death detection kit (Boehringer Mannheim, Germany) according to the manufacturer's instructions. After labeling, cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Cell-cycle and hypodiploidy analyses
Cells were trypsinized, washed 2 Â with PBS and fixed in 70% ethanol overnight at À201C. Cells were then washed 2 Â with PBS, and aliquots of 1 Â 10 6 cells were resuspended in 1 ml of PBS containing 1 mg/ml of RNase A and 0.5 mg/ml of PI. After 30 min of incubation, cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
RNA isolation and Northern blotting analysis
Total RNA was extracted from cells using the Qiagen RNeasy mini kit according to the manufacturer's protocol and was used for Northern blotting as previously described (Su et al., 1997 (Su et al., , 1999 . Briefly, 15 mg of RNA for each sample was denatured, electrophoresed in 1.2% agarose gels with 3% formaldehyde and transferred onto nylon membranes. The blots were probed with an a-32 P[dCTP]-labeled, full-length human mda-7 cDNA probe, then stripped and reprobed with an a-32 P[dCTP]-labeled human gapdh probe. Following hybridization, the filters were washed and exposed for autoradiography.
Preparation of cell extracts and Western blotting analysis
Protein lysates were prepared on ice in RIPA buffer (50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.1% SDS, 1% NP40 and 0.5% sodium deoxycholate) with freshly added 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mm sodium orthovanadate and 1 mg/ml aprotinin. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA). Aliquots of cell extracts containing 20-50 mg of total protein were resolved in 12% SDS-PAGE and transferred to 0.45 mm nitrocellulose membranes (Osmonics, Westborough, MA, USA). Filters were blocked for 1 h at room temperature in Blotto A (5% nonfat milk powder in TBS-T: 10 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.05% Tween 20), and then incubated for 1 h at room temperature in Blotto A containing a 1 : 1000 dilution of rabbit anti-MDA-7, anti-Bcl-2, anti-Bcl-x L , anti-Bax, anti-Bak polyclonal and anti-EF-1a monoclonal antibodies. After washing in TBS-T buffer (3 Â 5 min, RT), filters were incubated for 1 h at room temperature in Blotto A containing a 1 : 10 000 dilution of peroxidase conjugated anti-rabbit or anti-mouse secondary antibody (Amersham, Arlington Heights, IL, USA). After washing in TBS-T, ECL was performed according to the manufacturer's recommendation. Bcl-2-family protein expression as determined by Western blot analysis was quantitatively analysed via laser-scanning densitometry using the NIH Image Version 1.61 software. All results were normalized to EF-1a protein expression.
Statistical analysis
All the experiments were performed at least three times. The results are expressed as mean7s.e. Statistical comparisons were made using an unpaired two-tailed Student's t-test. A Po0.05 was considered to be significant.
